Marinus Pharmaceuticals was acquired by Immedica Pharma on February 7, 2025. As of February 7, 2025, Marinus Pharmaceuticals operates as a subsidiary of Immedica Pharma AB. The company now operates under Swedish rare disease ownership, positioning itself within a specialized pharma ecosystem focused on rare neurological conditions.
Cyborg Score Rationale
MRNS stock has declined 94.6% over the past year. The company has a market capitalization of $30.0M with approximately 55.2M shares outstanding, classifying it as a micro-cap stock. The acquisition by Immedica Pharma and substantial shareholder litigation reflect significant operational and financial challenges.
Top Insights
Dramatic stock decline of 94.6% YoY reflects failed drug development expectations and shareholder value destruction
Acquired by Immedica Pharma AB for $0.55/share in February 2025; now a private subsidiary with strategic refocusing opportunity
Lead product ZTALMY (ganaxolone) targets ultra-rare seizure disorders with limited market size, constraining revenue potential
Multiple shareholder lawsuits underscore governance concerns and fairness questions regarding the acquisition price and process
Named Competitors
ACADIA Pharmaceuticals — Neuropsychiatric drug developer
SAGE Therapeutics — Neuropsychiatric and seizure disorder treatments
Vertex Pharmaceuticals — Genetic disease treatments including seizure disorders
Alnylam Pharmaceuticals — RNAi therapeutics for rare diseases
Recent Developments
(February 2025) Acquisition by Swedish rare disease company Immedica Pharma AB completed at $0.55 per share
(January 2025) Multiple shareholder investigations initiated regarding fairness of acquisition price and process
(2024) Securities fraud class action lawsuits filed against company; Chief Medical Officer and CFO departed to competing firms
Open the full interactive Marinus Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.